Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats

The beneficial effects of bone marrow-derived mesenchymal stromal cell (MSC) administration following experimental stroke have already been described. Despite several promising characteristics, placenta-derived MSC have not been used in models of focal ischemia. The aim of the current study is to investigate the impact of intravenously transplanted placenta-derived MSC on post-stroke recovery. Permanent occlusion of the middle cerebral artery was induced in spontaneously hypertensive rats. MSC were obtained from the human maternal or fetal placenta and intravenously administered after 24 h (single transplantation) or after 8 h and 24 h (dual transplantation). Sensorimotor deficits were quantified for 60 days using the beam walk test and the modified Neurological Severity Score system. Infarct volume was determined in vivo by means of magnetic resonance imaging on days 1, 8, 29 and 60. Astroglial reactivity was semiquantitatively ascertained within a small and a broad region adjacent to the lesion border. The double infusion of placental MSC was superior to single transplantation in the functional tests. However, a significant difference to the control group in all outcome parameters was observed only for maternally derived MSC. These findings suggest that placental tissue constitutes a promising source for experimental stroke therapies

Translation individualisierter Diagnose- und Therapiekonzepte in die Klinik am Beispiel kardiologischer Erkrankung: Greifswald Approach to Individualized Medicine (GANI_MED)

Item does not contain fulltextBreast cancer during pregnancy (BCP), although rare, is becoming more common and treatment should be as similar as possible to that for nonpregnant young patients with breast cancer. A group of specialists convened to review current guidelines and provide guidance on how recent advances in breast cancer diagnosis and treatment can be adapted for pregnant patients. The majority of patients with BCP will be considered for treatment during the pregnancy. Premature delivery should be avoided whenever possible. Most treatments, including sentinel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-dense treatment can be safely given during pregnancy, after careful risk/benefit assessment for mother and child. Chemotherapy is contraindicated during the first trimester because of a higher risk of fetal malformations but is feasible in the second and third trimesters. Other treatments such as radiation therapy or anti-human epidermal growth receptor 2 treatment are in general not indicated during pregnancy but might be considered in some instances. Patient data should be collected in a systematic way whenever possible

Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients

Item does not contain fulltextBreast cancer during pregnancy (BCP), although rare, is becoming more common and treatment should be as similar as possible to that for nonpregnant young patients with breast cancer. A group of specialists convened to review current guidelines and provide guidance on how recent advances in breast cancer diagnosis and treatment can be adapted for pregnant patients. The majority of patients with BCP will be considered for treatment during the pregnancy. Premature delivery should be avoided whenever possible. Most treatments, including sentinel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-dense treatment can be safely given during pregnancy, after careful risk/benefit assessment for mother and child. Chemotherapy is contraindicated during the first trimester because of a higher risk of fetal malformations but is feasible in the second and third trimesters. Other treatments such as radiation therapy or anti-human epidermal growth receptor 2 treatment are in general not indicated during pregnancy but might be considered in some instances. Patient data should be collected in a systematic way whenever possible

GEMIS 4.0 - Globales Emissions-Modell Integrierter Systeme Ein Computerprogramm zur Umweltanalyse von Energie-, Transport und Stoffsystemen

GEMIS is a computer instrument for environmental impact and cost analysis of energy, transport and materials systems. Primary energy consumption, pollutant emissions and material flows of energy and transportation systems can be compared, and consumption and emissions can be calculated for all stages of energy production, conversion and utilisation. The current version 4.0 contains new data on new technologies, and the computer model was updated so that the data and scenarios can be used also in programs outside GEMIS. Data from other sources were included in the database as well.GEMIS - Globales Emissions-Modell Integrierter Systeme - ist ein Computer-Instrument zur Umwelt- und Kostenanalyse von Energie-, Transport- und Stoffsystemen. Das Modell ermoeglicht es, Primaerenergieverbrauch, Schadstoffemissionen und Stoffstroeme verschiedener Energie- und Verkehrssysteme zu vergleichen sowie Verbrauch und Emissionen auf jeder Stufe der Energiegewinnung, -umwandlung und -nutzung nachzuvollziehen. Mit der aktuellen Version 4.0 wurde GEMIS wiederum um weitere Daten insbesondere zu neuen Technologien ergaenzt. Ausserdem wurde das zu Grunde liegende Computermodell aktualisiert, was es unter anderem ermoeglicht, die Daten und Szenarien auch ausserhalb von GEMIS in fremden Programmen zu nutzen. Auch wurden weitere Daten von Dritten in die Datenbank aufgenommen. (orig.)Available from: http://www.oeko.de/service/gemis / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekSIGLEHessisches Ministerium fuer Umwelt, Landwirtschaft und Forsten, Wiesbaden (Germany)DEGerman